Echinomycin - OncoImmune

Drug Profile

Echinomycin - OncoImmune

Latest Information Update: 30 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoImmune
  • Class Cytostatic antibiotics
  • Mechanism of Action DNA synthesis inhibitors; Hypoxia-inducible factor-1 alpha inhibitors; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 29 Mar 2016 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) prior to March 2016 (OncoImmune pipeline, March 2016)
  • 29 Mar 2016 Pharmacodynamics data from a preclinical trials in Acute myeloid leukaemia and Lymphoma released by Oncoimmune (Oncoimmune website, March 2016)
  • 21 May 2015 Echinomycin receives Orphan Drug status for Acute myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top